EA201991105A1 - Методы оценки риска с использованием общей и специфической неклеточной днк - Google Patents

Методы оценки риска с использованием общей и специфической неклеточной днк

Info

Publication number
EA201991105A1
EA201991105A1 EA201991105A EA201991105A EA201991105A1 EA 201991105 A1 EA201991105 A1 EA 201991105A1 EA 201991105 A EA201991105 A EA 201991105A EA 201991105 A EA201991105 A EA 201991105A EA 201991105 A1 EA201991105 A1 EA 201991105A1
Authority
EA
Eurasian Patent Office
Prior art keywords
total
specific non
risk assessment
cellular dna
assessment methods
Prior art date
Application number
EA201991105A
Other languages
English (en)
Inventor
Аой Томита Митчелл
Майкл Митчелл
Карл Стамм
Original Assignee
Дзе Медикал Колледж Оф Висконсин, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/030293 external-priority patent/WO2017190106A1/en
Application filed by Дзе Медикал Колледж Оф Висконсин, Инк. filed Critical Дзе Медикал Колледж Оф Висконсин, Инк.
Publication of EA201991105A1 publication Critical patent/EA201991105A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2560/00—Nucleic acid detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для оценки риска путем определения уровней общих и специфических неклеточных нуклеиновых кислот (таких как ДНК) у индивидуума. Описанные здесь способы и композиции могут быть применены для определения риска развития такого состояния, как отторжение трансплантата.
EA201991105A 2016-11-02 2017-11-02 Методы оценки риска с использованием общей и специфической неклеточной днк EA201991105A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416689P 2016-11-02 2016-11-02
PCT/US2017/030293 WO2017190106A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-target number
PCT/US2017/059808 WO2018085603A1 (en) 2016-11-02 2017-11-02 Methods for assessing risk using total and specific cell-free dna

Publications (1)

Publication Number Publication Date
EA201991105A1 true EA201991105A1 (ru) 2020-01-27

Family

ID=62076613

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991105A EA201991105A1 (ru) 2016-11-02 2017-11-02 Методы оценки риска с использованием общей и специфической неклеточной днк

Country Status (10)

Country Link
US (1) US20190367972A1 (ru)
EP (1) EP3535413A1 (ru)
JP (1) JP2019534016A (ru)
CN (1) CN110114477A (ru)
AU (1) AU2017355464A1 (ru)
CA (1) CA3042696A1 (ru)
EA (1) EA201991105A1 (ru)
IL (1) IL266382A (ru)
MX (1) MX2019005199A (ru)
WO (1) WO2018085603A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2854058A3 (en) 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
WO2012108920A1 (en) 2011-02-09 2012-08-16 Natera, Inc Methods for non-invasive prenatal ploidy calling
EP3561075A1 (en) 2014-04-21 2019-10-30 Natera, Inc. Detecting mutations in tumour biopsies and cell-free samples
EP3294906B1 (en) 2015-05-11 2024-07-10 Natera, Inc. Methods for determining ploidy
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
CN110177874A (zh) * 2016-11-02 2019-08-27 威斯康星州立大学医学院 用于使用错配扩增和统计方法来评估风险的方法
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CA3067637A1 (en) * 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
WO2019200228A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
WO2019217918A1 (en) * 2018-05-10 2019-11-14 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) * 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021207244A1 (en) * 2020-04-06 2021-10-14 The Medical College Of Wisconsin, Inc. Methods for assessing the severity of, and for inhibiting, pro-inflammatory responses with total cell-free dna
AU2022226186A1 (en) * 2021-02-25 2023-09-07 Natera, Inc. Methods for detection of donor-derived cell-free dna in transplant recipients of multiple organs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057061A1 (en) * 2009-11-06 2011-05-12 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive diagnosis of graft rejection in organ transplant patients
WO2011118603A1 (ja) * 2010-03-24 2011-09-29 凸版印刷株式会社 競合プライマーによる標的塩基配列の検出方法
US10131947B2 (en) * 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
CA3209140A1 (en) * 2012-04-19 2013-10-24 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
EP3004388B2 (en) * 2013-05-29 2023-05-31 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
WO2015138997A1 (en) * 2014-03-14 2015-09-17 Caredx, Inc. Methods of monitoring immunosuppressive therapies in a transplant recipient
MA39951A (fr) * 2014-05-09 2017-03-15 Lifecodexx Ag Détection de l'adn provenant d'un type spécifique de cellule et méthodes associées
US10435750B2 (en) * 2014-07-03 2019-10-08 Multiplicom N.V. Methods for non-invasive detection of transplant health or rejection
US10704104B2 (en) * 2014-10-20 2020-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening a subject for a cancer
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
BR112017023232A2 (pt) * 2015-04-30 2018-08-07 Medical College Of Wisconsin Inc pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células
EP3449018A4 (en) * 2016-04-29 2019-11-06 The Medical College of Wisconsin, Inc. REAL-TIME PCR WITH MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA) FOR THE EVALUATION OF FETAL WELL-BEING

Also Published As

Publication number Publication date
MX2019005199A (es) 2019-10-14
CA3042696A1 (en) 2018-05-11
WO2018085603A1 (en) 2018-05-11
IL266382A (en) 2019-06-30
AU2017355464A1 (en) 2019-05-30
CN110114477A (zh) 2019-08-09
JP2019534016A (ja) 2019-11-28
EP3535413A1 (en) 2019-09-11
US20190367972A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
MX2017013878A (es) Amplificación de discordancias optimizadas multiplicadas (moma) - reacción en cadena de polimerasa (pcr) en tiempo real, para evaluar el ácido desoxirribonucleico (adn) libre de celula.
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
EA201890619A1 (ru) КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
MX2020001809A (es) Metodos para determinar acido desoxirribonucleico circulante de donante sin genotipo de donante.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EA201791184A1 (ru) Днк-примеси в композиции, содержащей парвовирусный вирион
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
DK3138489T3 (da) Sæt til bestemmelse af en analytkoncentration
EA201892491A1 (ru) Пцр в реальном времени с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) для анализа злокачественных новообразований
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
WO2017044993A3 (en) Nucleic acid analysis by joining barcoded polynucleotide probes
BR112016021679A2 (pt) proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112017023473A2 (pt) método de detecção e quantificação de ácido nucleico e composições
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
EA201691702A1 (ru) Химерные белки мти
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
MX2019011702A (es) Ensayos de inmunogenicidad mejorados.